Safety and efficacy of omaveloxolone in patients with mitochondrial myopathy
- 18 February 2020
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 94 (7), e687-e698
- https://doi.org/10.1212/wnl.0000000000008861
Abstract
Objective To investigate the safety and efficacy of escalating doses of the semi-synthetic triterpenoid omaveloxolone in patients with mitochondrial myopathy. Methods In cohorts of 8–13, 53 participants were randomized double-blind to 12 weeks of treatment with omaveloxolone 5, 10, 20, 40, 80, or 160 mg, or placebo. Outcome measures were change in peak cycling exercise workload (primary), in 6-minute walk test (6MWT) distance (secondary), and in submaximal exercise heart rate and plasma lactate (exploratory). Results No differences in peak workload or 6MWT were observed at week 12 with omaveloxolone treatment vs placebo for all omaveloxolone dose groups. In contrast, omaveloxolone 160 mg reduced heart rate at week 12 by 12.0 ± 4.6 bpm (SE) during submaximal exercise vs placebo, p = 0.01, and by 8.7 ± 3.5 bpm (SE) vs baseline, p = 0.02. Similarly, blood lactate was 1.4 ± 0.7 mM (SE) lower vs placebo, p = 0.04, and 1.6 ± 0.5 mM (SE) lower vs baseline at week 12, p = 0.003, with omaveloxolone 160 mg treatment. Adverse events were generally mild and infrequent. Conclusions Omaveloxolone 160 mg was well-tolerated, and did not lead to change in the primary outcome measure, but improved exploratory endpoints lowering heart rate and lactate production during submaximal exercise, consistent with improved mitochondrial function and submaximal exercise tolerance. Therefore, omaveloxolone potentially benefits patients with mitochondrial myopathy, which encourages further investigations of omaveloxolone in this patient group. Clinicaltrials.gov identifier NCT02255422. Classification of evidence This study provides Class II evidence that, for patients with mitochondrial myopathy, omaveloxolone compared to placebo did not significantly change peak exercise workload.Keywords
This publication has 22 references indexed in Scilit:
- Combined Training Enhances Skeletal Muscle Mitochondrial Oxidative Capacity Independent of AgeJournal of Clinical Endocrinology & Metabolism, 2015
- Nrf2 affects the efficiency of mitochondrial fatty acid oxidationBiochemical Journal, 2014
- Acute exercise stress activates Nrf2/ARE signaling and promotes antioxidant mechanisms in the myocardiumFree Radical Biology & Medicine, 2012
- Treatment for mitochondrial disordersEmergencias, 2011
- The effect of training on the expression of mitochondrial biogenesis- and apoptosis-related proteins in skeletal muscle of patients with mtDNA defectsAmerican Journal of Physiology-Endocrinology and Metabolism, 2007
- Endurance training and detraining in mitochondrial myopathies due to single large-scale mtDNA deletionsBrain, 2006
- Aerobic training is safe and improves exercise capacity in patients with mitochondrial myopathyBrain, 2006
- Exercise training in mitochondrial myopathy: A randomized controlled trialMuscle & Nerve, 2005
- The spectrum of exercise tolerance in mitochondrial myopathies: a study of 40 patientsBrain, 2003
- Apoptosis and ROS Detoxification Enzymes Correlate with Cytochrome c Oxidase Deficiency in Mitochondrial EncephalomyopathiesMolecular and Cellular Neuroscience, 2001